Shares of Bio-Techne Corporation (NASDAQ: TECH) surged over 5% in pre-market trading on Tuesday, after the life sciences company reported better-than-expected financial results for the first quarter of fiscal 2025.
For the three months ended September 30, 2024, Bio-Techne posted adjusted earnings per share of $0.42, surpassing analysts' consensus estimate of $0.38. Total revenue rose to $289.5 million, exceeding the forecasted $280.3 million.
The strong performance was driven by robust demand across Bio-Techne's product portfolio, particularly in its core Protein Sciences segment. The company also cited favorable foreign exchange rates as a tailwind.
"Bio-Techne's first quarter results reflect the continued execution of our core strategic priorities," said CEO Chuck Kummeth. "We are well-positioned to capitalize on growing end-market opportunities and remain committed to delivering long-term sustainable growth."Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.